ArticleJournal of molecular histology2026
EpCAM as a novel target of MARCH8: implications for esophageal squamous cell carcinoma progression.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests a crucial role of MARCH8, a membrane-associated RING-E3 ubiquitin ligase, in cancer progression by regulating the turnover of cancer-related proteins. Our previous research identified potential MARCH8 targets using an RNAi-coupled proteomics approach, revealing that MARCH8 mediates the proteasomal degradation of E-cadherin and β2m, contributing to Esophageal Squamous Cell Carcinoma (ESCC) progression. Additionally, EpCAM emerged as a key target, and this study aims to investigate how MARCH8 regulates EpCAM stability and its implications in tumor migration. Herein, Co-immunoprecipitation (Co-IP) and Western Blotting (WB) demonstrated that MARCH8 directly interacts with EpCAM and regulates its turnover by ubiquitination and proteasomal degradation. Further, MARCH8-EpCAM co-localization was observed in ESCC cells using Immunofluorescence (IF). Additionally, Immunohistochemistry (IHC) analysis in ESCC tissues revealed a significant inverse correlation between MARCH8 and EpCAM expression (r = -0.6730, p < 0.0001). Interestingly, EpCAM showed a context-dependent expression in esophageal tissues. Adjacent non-malignant esophageal squamous epithelium showed no detectable EpCAM staining, superficial tumor regions displayed membranous EpCAM expression, whereas tumor cells at the deeper invasive front exhibited markedly reduced or lost EpCAM expression. Consistently, scratch assay coupled with IF and IHC analysis further demonstrated reduced EpCAM expression in migrating ESCC cells. Overexpression studies further revealed an inverse relationship between MARCH8 and EpCAM in migration, invasion, and β-catenin signaling, as shown by invasion/migration assays and WB analysis. Collectively, these findings establish EpCAM as a novel target of MARCH8. Given that loss of EpCAM is associated with migratory phenotypes and that MARCH8 promotes ESCC progression, MARCH8-driven EpCAM degradation may contribute to enhanced tumor cell migration and disease progression.
Indexed as
Identifiers
41870734What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.